With revenues of €248 million1 in 2018 and a record of vigorous growth, Chiesi Ltd. is now the number one affiliate in the Chiesi group.
In the UK, Chiesi Ltd. employs just over 400 dedicated employees, who are based out of our head office in Manchester, the Research and Development centre in Chippenham, and across the UK as part of our experienced field-based sales teams.
As with every part of the Chiesi group, we embrace a shared set of values and a common code of ethical conduct. This demands the highest standards of reliability, transparency, and individual accountability, in everything we do. It emphasises the importance of collaborative working, putting people first and exchanging knowledge. Implicit in all of these values is a responsible attitude to the social and environmental impact of our actions, in this regard, Chiesi was proud to achieve the B Corp certification in June 2019.
We work on important therapy areas, such as organ transplantation and rare diseases, alongside our treatments for respiratory conditions, Chiesi Ltd. is poised to extend further still the contribution we make to public health in the UK. As the winners of an independent Top Employer Award in the UK and Europe for the seventh consecutive year, ours is a culture where innovation and professional excellence flourish.
Chiesi Farmaceutici S.p.A. is an international, research-based, pharmaceutical company, based in Parma, Italy. With over 80 years’ experience, Chiesi is dedicated to the research, development and sales of innovative, therapeutic prescription medicines in the field of respiratory, neonatology, transplant medicine and rare diseases. With a turnover of €1,768 million we are among the top 50 pharmaceutical companies in the world.
The Company was founded in 1935, as a family firm. Chiesi spans the globe, employing more than 5,600 people in 27 affiliates worldwide and sells its products in more than 80 countries.2
We embrace innovation which is a constant driver to our continued success. Products wholly, or partially, developed by Chiesi account for 81% of our sales1, and our investment in Research and Development currently stands at a record €382 million – 21.6% of our revenue. Chiesi ‘firsts’ include the first stem cell product approved in Europe and new options for serious genetic diseases.
Chiesi Ltd. was established in 1999 with the acquisition of Trinity Pharmaceuticals (by Chiesi S.p.A), whose ethos, values and specialist expertise perfectly complemented those of the wider Chiesi group.
UK-CHI-1900246 August 2019